NASDAQ:BIOL - BIOLASE Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.43 +0.01 (+0.41 %) (As of 03/18/2019 04:00 PM ET)Previous Close$2.42Today's Range$2.34 - $2.4852-Week Range$0.91 - $2.98Volume81,000 shsAverage Volume60,613 shsMarket Capitalization$51.34 millionP/E Ratio-2.86Dividend YieldN/ABeta2.32 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California. Receive BIOL News and Ratings via Email Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone949-361-1200Debt Debt-to-Equity Ratio0.98 Current Ratio2.09 Quick Ratio0.85Price-To-Earnings Trailing P/E Ratio-2.86 Forward P/E Ratio-3.16 P/E GrowthN/A Sales & Book Value Annual Sales$46.15 million Price / Sales1.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book1.70Profitability EPS (Most Recent Fiscal Year)($0.85) Net Income$-21,520,000.00 Net Margins-46.62% Return on Equity-95.21% Return on Assets-46.54%Miscellaneous EmployeesN/A Outstanding Shares21,126,000Market Cap$51.34 million Next Earnings Date5/1/2019 (Estimated) OptionableNot Optionable BIOLASE (NASDAQ:BIOL) Frequently Asked Questions What is BIOLASE's stock symbol? BIOLASE trades on the NASDAQ under the ticker symbol "BIOL." When did BIOLASE's stock split? How did BIOLASE's stock split work? BIOLASE's stock reverse split on the morning of Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split. How were BIOLASE's earnings last quarter? BIOLASE Inc (NASDAQ:BIOL) issued its earnings results on Thursday, August, 9th. The medical technology company reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20). The medical technology company had revenue of $12.15 million for the quarter. BIOLASE had a negative return on equity of 95.21% and a negative net margin of 46.62%. View BIOLASE's Earnings History. When is BIOLASE's next earnings date? BIOLASE is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for BIOLASE. What is the consensus analysts' recommendation for BIOLASE? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE. Has BIOLASE been receiving favorable news coverage? News stories about BIOL stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIOLASE earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are some of BIOLASE's key competitors? Some companies that are related to BIOLASE include Palatin Technologies (PTN), Palatin Technologies (PTN), Recro Pharma (REPH), Novavax (NVAX), Poxel (PXXLF), Nature's Sunshine Products (NATR), AcelRx Pharmaceuticals (ACRX), Synlogic (SYBX), Joint (JYNT), VBI Vaccines (VBIV), NicOx (NICXF), Compugen (CGEN), OncoCyte (OCX), CorMedix (CRMD) and CorMedix (CRMD). What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Idera Pharmaceuticals (IDRA), Magnachip Semiconductor (MX), Athersys (ATHX), Merrimack Pharmaceuticals (MACK), GTX (GTXI), SLS International (SLS), Prana Biotechnology (PRAN) and CTI BioPharma (CTIC). Who are BIOLASE's key executives? BIOLASE's management team includes the folowing people: Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)Mr. John R. Beaver, Exec. VP & CFO (Age 58)Mr. Richard R. Whipp, VP of Operations (Age 67)Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)Mr. Daniel Merkin, National Sales Director (Age 46) Who are BIOLASE's major shareholders? BIOLASE's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Trellus Management Company LLC (0.70%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE. Which major investors are buying BIOLASE stock? BIOL stock was purchased by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE. How do I buy shares of BIOLASE? Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BIOLASE's stock price today? One share of BIOL stock can currently be purchased for approximately $2.43. How big of a company is BIOLASE? BIOLASE has a market capitalization of $51.34 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. What is BIOLASE's official website? The official website for BIOLASE is http://www.biolase.com. How can I contact BIOLASE? BIOLASE's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected] MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 198 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 387MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/18/2019 by MarketBeat.com StaffFeatured Article: What factors cause inflation to rise?